Josko Mitrovic

Prof. Dr. Josko Mitrovic

MD, PhD, Assistant Professor, Division of Clinical Immunology, Allergology and Rheumatology, Department of Internal Medicine, School of Medicine University of Zagreb, Dubrava University Hospital, Avenija Gojka Šuška 6, 10 000, Zagreb, Croatia.
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
JMJosko Mitrovic
Josko Mitrovic
SHStela Hrkač
Stela Hrkač
JTJosip Tečer
Josip Tečer
MGMajda Golob
Majda Golob
APAnja Ljilja Posavec
Anja Ljilja Posavec
LGLovorka Grgurevic
Lovorka Grgurevic
Rheumatoid arthritis (RA) is among the most prevalent and debilitating autoimmune inflammatory chronic diseases. Although it is primarily characterized by destructive peripheral arthritis, it is a systemic disease, and RA-related extraarticular manifestations (EAMs) can affect almost every organ, exhibit a multitude of clinical presentations, and can even be asymptomatic. Importantly, EAMs largely contribute to the quality of life and mortality of RA patients, particularly substantially increased risk of cardiovascular disease (CVD) which is the leading cause of death in RA patients. In spite of known risk factors related to EAM development, a more in-depth understanding of its pathophysiology is lacking. Improved knowledge of EAMs and their comparison to the pathogenesis of arthritis in RA could lead to a better understanding of RA inflammation overall and its initial phases. Taking into account that RA is a disorder that has many faces and that each person experiences it and responds to treatments differently, gaining a better understanding of the connections between the joint and extra-joint manifestations could help to create new treatments and improve the overall approach to the patient.

1 March 2021 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
SPSilva Pukšić
Silva Pukšić
JMJosko Mitrovic
Josko Mitrovic
MČMelanie-Ivana Čulo
Melanie-Ivana Čulo
MŽMarcela Živković
Marcela Živković
BOBiserka Orehovec
Biserka Orehovec
JMJadranka Morović-Vergles
Jadranka Morović-Vergles
To explore the feasibility and effectiveness of a yoga program in improving health-related quality of life (HQOL), physical and psychological functioning in rheumatoid arthritis (RA) patients. Single-centre parallel-arms randomized controlled trial comparing yoga (n = 30) and education control group (n = 27). Tertiary care University hospital. A 12-week yoga program, based on the Yoga in Daily Life system, included 2x weekly/90-minute sessions. The control group had 1xweekly/60-minute educational lectures on arthritis-related topics. Assessments were performed at baseline, 12 (post-intervention) and 24 weeks (follow-up). The primary outcome was change in The Short Form-36 (SF-36) HQOL at 12 weeks. Linear regression analysis was adjusted for baseline scores. No significant between-group differences were found for SF-36 (all p > 0.05). At 12 weeks the adjusted mean difference between groups favoured yoga for Functional Assessment of Chronic Illness Therapy-fatigue (5.08 CI 1.29 to 8.86; p = 0.009) and Hospital Anxiety and Depression Scale (HADS)-depression (-1.37 CI -2.38 to -0.36); p = 0.008) and at 24 weeks for HADS-anxiety (-1.79 CI -3.34 to - 0.23; p = 0.025), while the impact on fatigue was sustained (5.43 CI 1.33 to 9.54, p = 0.01). The program had no impact on RA disease activity. Feasibility outcomes included recruitment rate 16 %, retention 80.7 %, and adherence to yoga 87.5 vs 82.7 % for control. No serious adverse events were recorded. Yoga in Daily Life program was not associated with change in health-related quality of life of RA patients. Significant improvements in fatigue and mood were observed at postintervention and follow-up. This yoga program was found feasible and safe for patients and may complement standard RA treat-to-target strategy.

17 April 2021 in Molecules
Verified
Journal Article
Open access
PDF file
VTVesna Sredoja Tišma
Vesna Sredoja Tišma
SBStela Bulimbasic
Stela Bulimbasic
DLDanica Galešić Ljubanović
Danica Galešić Ljubanović
KGKresimir Galesic
Kresimir Galesic
JMJadranka Morovic-Vergles
Jadranka Morovic-Vergles
MJMorana Jaganjac
Morana Jaganjac
Small-vessel vasculitis (SVV) is the inflammation of the vessel wall that can result in hemorrhage and/or ischemia. Among the histological findings in SVV are increased infiltrating neutrophils, which, due to their oxidative burst and myeloperoxidase activity, release excessive reactive oxygen species, triggering a chain reaction of lipid peroxidation and yielding reactive aldehydes such as acrolein. The implication of oxidative stress in the pathogenesis of SVV was studied, focusing on acrolein immunohistochemistry in the affected skin vessels and systemic stress response. Samples from SVV patients and healthy subjects were collected and analyzed for total serum peroxides, total antioxidant capacity, inflammatory and immunological parameters, as well as for the presence of acrolein–protein adducts in the skin tissue specimens. The obtained data showed that systemic redox homeostasis and iron metabolism are altered in SVV patients. Possible biomarkers in the evaluation of oxidative status, disease activity and prevalence were indicated. Furthermore, a strong correlation between the accumulation of acrolein–protein adducts in the skin and the progression of the disease was revealed. Thus, the results of this study demonstrate that SVV is not only associated with systemic oxidative stress but also with tissue-specific oxidative stress that promotes acrolein formation and protein modification correlating with the severity of cutaneous vasculitis.

24 August 2023 in Clinical Case Reports
Verified
Journal Article
Open access
MBMarina Božan
Marina Božan
VLVesna Vukičević Lazarević
Vesna Vukičević Lazarević
IMIvan Marković
Ivan Marković
JMJadranka Morovic-Vergles
Jadranka Morovic-Vergles
JMJosko Mitrovic
Josko Mitrovic
Key Clinical Message: Alpha‐gal syndrome is an immunoglobulin E‐mediated hypersensitivity characterized by delayed allergic reactions to ingested products containing alpha‐gal carbohydrate. We present a patient with recurrent urticaria and suspected repaglinide hypersensitivity, who was eventually diagnosed with alpha‐gal syndrome, wanting to emphasize possible drug allergy misdiagnosis and required caution with the medication choice.


27 May 2010 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ZRZeljko Romic
Zeljko Romic
LDLovorka Derek
Lovorka Derek
VBVitomir Burek
Vitomir Burek
AUAdriana Unic
Adriana Unic
TSTihana Serdar
Tihana Serdar
MPMladen Petrovecki
Mladen Petrovecki